# 001882 · claims · run 39542214672

Model `claude-opus-5-5`, Claude Code 2.1.284, permission mode `default`. Tools: `Task`, `Bash`, `DesignSync`, `Edit`, `EnterWorktree`, `ExitWorktree`, `Glob`, `Grep`, `ListAgents`, `NotebookEdit`, `Read`, `ReportFindings`, `SendMessage`, `Skill`, `TaskCreate`, `TaskGet`, `TaskList`, `TaskStop`, `TaskUpdate`, `ToolSearch`, `WebFetch`, `WebSearch`, `Write`.

**Agent calls Bash**

```bash
cat docs/protocol.md; ls claims/001453/ paper/ claims/001882 2>&1
```

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
sed -n '/^## Reader/,/^## Author/p' docs/protocol.md
```

```
## Reader

### 1. Get the paper

The workflow puts the paper's full text, and its PDF where there is one, under
`paper/`: the main text, the Methods, and the supplement. Read the text; open
the PDF only to read a figure or a table the text garbles. If the full text is
not there, or lacks the Methods or a supplement the results rest on, stop:
write no claims, and end with a report that names what is missing, so that it
can be supplied. Never write claims from the abstract. Do not copy figures.
Do not look at the dataset's data: its title and description on the archive
are enough to know which paper and which experiments it is meant to hold.

### 2. Read the paper's code

Read the code the paper links to before writing criteria. Say what it holds,
and record the repository and commit read. Where the Methods leave a choice
open and the code settles it, follow the code and say so. Where they disagree,
follow the Methods for the main result and name the code's choice as a
variant. When more sources disagree (the Methods, the analysis code, the
[... 116 more lines not kept]
```

**Agent calls Bash**

```bash
cat claims/001453/*.yaml | head -150; wc -c paper/*.txt
```

**Agent calls Read**

```json
{
 "file_path": "paper/10.3390-genes16010043.txt"
}
```

Result: not kept, because it reads the paper's text.

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
python3 - <<'E'
t=open('paper/10.3390-genes16010043.txt').read()
i=t.find('References 1.')
print(len(t), i)
import re
for k in ['Supplement','supplement','github','code','Code']:
    print(k,[m.start() for m in re.finditer(k,t)][:10])
print(t[-1500:])
E
grep -rn "001882" --include=*.yaml --include=*.md --include=*.json --include=*.csv . | grep -v transcripts | head; ls
```

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
sed -n 7585,7640p targets/dandisets.json; sed -n 1865,1890p papers/manifest.yaml
```

```
{
     "doi": "10.22002/d1.1991",
     "title": "CalMS21 - Caltech Mouse Social Interactions (Sun et al., 2021)",
     "relation": "IsDerivedFrom",
     "resource_type": null,
     "preprint": false
    }
   ],
   "catalystneuro": [
    "contributor Mayorquin, Heberto of CatalystNeuro"
   ]
  },
  {
   "dandiset": "001882",
   "name": "SalidoLab 2024.Genes paper. WVU humans with IMPG1/2 mutations",
   "published_version": "0.260701.1757",
   "asset_count": 13,
   "size_gb": 0.99,
   "data_standards": [],
   "species": [],
[... 62 more lines not kept]
```

**Agent**

The full text and Methods are there, the paper names no supplement, and it links no code. Next I'm checking the claims schema, then I'll write the file.

**Agent calls Bash**

```bash
ls schemas; python3 -c "
import json,glob
for f in glob.glob('schemas/*claim*'):
    print(f); print(open(f).read()[:6000])
"; sed -n 150,400p claims/001453/*.yaml | grep -nE "^(- id|  [a-z_]+:)" | sort -u -k2 | head -40
```

```
attempt.schema.json
claims.schema.json
entry.schema.json
schemas/claims.schema.json
{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "title": "Claims proposed for one target (a dataset and one of its papers)",
  "description": "Draft. To be revised after the pilot.",
  "type": "object",
  "additionalProperties": false,
  "required": [
    "schema_version",
    "dataset",
    "paper",
    "claims"
  ],
  "properties": {
    "schema_version": {
      "const": 2
    },
[... 185 more lines not kept]
```

**Agent calls Bash**

```bash
python3 -c "
import json;s=json.load(open('schemas/claims.schema.json'));print(json.dumps(s['\$defs'],indent=1)[:3000]); print(json.dumps(s['properties'].get('checks',''),indent=0)[:300])"; ls tools
```

```
{
 "expected": {
  "type": "object",
  "additionalProperties": false,
  "required": [
   "quantity",
   "value"
  ],
  "properties": {
   "quantity": {
    "type": "string"
   },
   "value": {
    "type": "number"
   },
   "tolerance": {
    "type": "number",
    "minimum": 0
   },
   "unit": {
[... 111 more lines not kept]
```

**Agent**

The paper is complete as fetched: Europe PMC full text of the version of record, with Methods and Tables 1 to 4 inline. It names no supplement and links no code. Writing the claims file now.

**Agent calls Bash**

```bash
sed -n 1,80p tools/claims_check.py | head -60
```

```
"""Check a claims file against the full text of its paper.

    python tools/claims_check.py claims/<dandiset>/<doi>.yaml paper/<text>.txt [more texts ...]

Validates the file against schemas/claims.schema.json, checks every quote word for word
(fragments split on "...", found in order) and looks for every recorded p-value and
confidence-interval bound in the text. The text may be plain text, HTML or JATS XML; several
files (a paper and its supplement) are searched together. A value printed in a form the
checker does not know (a garbled PDF glyph, "p = 0.04, 0.05 and 0.16") is reported, to be
confirmed by reading. Exits non-zero on any problem.
"""

from __future__ import annotations

import html
import re
import sys
import unicodedata
from pathlib import Path

[... 41 more lines not kept]
```

**Agent calls Write**

```json
{
 "file_path": "claims/001882/10.3390-genes16010043.yaml",
 "content": "# Claims for Yuan, Chatterjee, Leys, Odom & Salido (2025), Genes 16(1):43, on dandiset 001882.\n# Written by an agent (model \"claude-opus-5-5\", Claude Code in GitHub Actions), 2026-10-21,\n# protocol pilot-10 as stated in docs/protocol.md.\n#\n# Text read: the version of record (MDPI Genes, open access), full text as served by Europe PMC\n# (PMC11764596): Introduction, Methods, Results, Discussion, the legends of Figures 1 to 4 and\n# Tables 1 to 4 inline. No PDF was supplied; the tables were read from the text, where they\n# are flattened but legible. The paper names no supplementary material, and none was used. It\n# links no analysis code; no code was read. Its Data Availability Statement says \"No new data\n# were created or analyzed in this study\", although the dandiset is described by the paper.\n#\n# The dataset (title \"SalidoLab 2024.Genes paper. WVU humans with IMPG1/2 mutations\") is\n# meant to hold the patient data of this paper. Its data were not looked at.\n#\n# Data the paper used, as it reports them:\n# - Cohort. 480 patients with inherited retinal diseases (IRDs) seen at the IRDs Clinic,\n#   Department of Ophthalmology and Visual Sciences, West Virginia University, March 2015 to\n#   June 2024. All had next-generation sequencing panels from various laboratories; the seven\n#   patients described were tested by INVITAE (248 to 330 retinal dystrophy genes).\n# - Seven patients with IMPG1 or IMPG2 variants, named by sex and age: F32, M83 (retinitis\n#   pigmentosa, RP), M75, M82, M73, F57, M34 (vitelliform macular dystrophy, VMD). Table 1 gives\n#   for each the gene, cDNA and protein change, zygosity and inheritance, mutation type,\n#   diagnosis and best corrected visual acuity (BCVA, Snellen) of each eye (OD right, OS left).\n# - Measures per patient and eye. BCVA (Snellen charts); color fundus photography (FF) and\n#   fundus autofluorescence (FAF) on an Optos system; fluorescein angiography (FA, also written\n#   FFA) and spectral domain optical coherence tomography (SD-OCT) on a Heidelberg Spectralis;\n#   Goldmann visual fields (GVF) for the RP patients. The Discussion also cites an\n#   electro-oculogram (EOG) for M73. Figure 2 shows the RP patients, Figure 3 the VMD patients,\n#   right eye above and left eye below.\n# - In silico analyses of the variants, which use no patient recordings: pathogenicity scores\n#   (SIFT, PolyPhen-2, MutationTaster, CADD, FATHMM; Table 2), stability changes (mCSM, SDM,\n#   DUET, iMutant, MuPRO; Table 3), interatomic interactions (DynaMut on I-TASSER models;\n#   Figure 4) and physicochemical properties of IMPG1 (ExPASy ProtParam; Table 4). Population\n#   frequencies come from gnomAD. None of the models or tool outputs is said to be deposited.\n#\n# The paper reports no statistical test or interval for any finding; no claim has statistics.\nschema_version: 2\ndataset:\n  archive: dandi\n  id: \"001882\"\npaper: doi:10.3390/genes16010043\nclaims:\n- id: cohort-prevalence\n  statement: Of 480 IRD patients in the cohort, 7 (1.45%) carried IMPG1 or IMPG2 mutations; 2\n    (0.41%) were diagnosed with RP and 5 (1.04%) with VMD.\n  source: Results, opening paragraph (before 3.1)\n  quote: In our study, 7 out of 480 patients with IRDs (1.45%) were found to have mutations in IMPG\n    genes. Of these, two patients (0.41%) were diagnosed with RP, while five patients (1.04%)\n    exhibited characteristics of VMD.\n  expected:\n  - quantity: patients with IMPG1 or IMPG2 mutations\n    value: 7\n    tolerance: 0\n  - quantity: cohort size\n    value: 480\n    tolerance: 0\n  - quantity: patients with IMPG mutations among IRD patients\n    value: 1.45\n    tolerance: 0.145\n    unit: percent\n  - quantity: patients with RP among IRD patients\n    value: 0.41\n    tolerance: 0.041\n    unit: percent\n  - quantity: patients with VMD among IRD patients\n    value: 1.04\n    tolerance: 0.104\n    unit: percent\n  criterion: Counts are of patients and must match exactly (tolerance 0, as a count of people\n    has no measurement error); percentages take the default 10%. The carriers and their\n    diagnoses are counted from the dataset; the denominator of 480 is the cohort of Methods 2.1\n    (IRDs Clinic, March 2015 to June 2024). If the dataset holds only the seven carriers, the\n    numerators are tested and the denominator is recorded as taken from the paper. The paper\n    prints 1.45% and 0.41% where 7/480 and 2/480 give 1.458% and 0.417%; both truncation and\n    rounding fall within tolerance, so this does not change the outcome. The Discussion's \"1 in\n    68\" is 480/7 and is tested with the same counts.\n- id: all-caucasian\n  statement: All seven patients with IMPG mutations were Caucasian.\n  source: Results, opening paragraph (before 3.1)\n  quote: All seven patients with IMPG mutations were Caucasian.\n  criterion: Reproduced when the dataset records race or ancestry as Caucasian (white,\n    European) for all seven patients; not reproduced when any is recorded otherwise; blocked\n    when the dataset does not record it.\n- id: table1-genotypes\n  statement: The seven patients carry the variants of Table 1 (F32 IMPG1 c.2218C>T p.Leu740Phe\n    heterozygous; M83 IMPG2 c.3056G>A p.Cys1019Tyr and c.391C>T p.Arg131Cys, compound\n    heterozygous; M75 IMPG1 c.1269C>A p.Asp423Glu heterozygous; M82 IMPG2 c.745C>T p.Leu249Phe\n    heterozygous; M73 and F57 IMPG2 c.2890C>T p.Arg964* heterozygous; M34 IMPG2 c.3262C>T\n    p.Arg1088* heterozygous).\n  source: Table 1; Results, opening paragraph (before 3.1)\n  quote: All the patients are represented in Table 1.\n  criterion: For each of the seven patients, the gene, cDNA change, protein change and\n    zygosity in the dataset are compared with Table 1. Table 1 writes the gene of F32 as \"IMGP1\";\n    the text (3.1, Figure 1) makes it IMPG1, and IMPG1 is the reading used. Reproduced when all\n    seven patients match in every field; partially reproduced when some but not all do; not\n    reproduced when none does. Reference transcripts are not named in the paper, so a cDNA\n    position that differs only by a transcript offset, with the same protein change, is\n    reported and counted as a match.\n- id: table1-diagnosis-sex-age\n  statement: F32 (female, 32 years) has sectoral RP and M83 (male, 83) RP; M75 (male, 75), M82\n    (male, 82), M73 (male, 73), F57 (female, 57) and M34 (male, 34) have VMD.\n  source: Table 1\n  inferred: Sex, age and diagnosis per patient are read from Table 1 and the patient\n    identifiers; no single sentence states them all.\n  criterion: Diagnosis and sex must match exactly for each patient. Age is the number in the\n    identifier and the \"N-year-old\" of section 3; the paper does not say at which date it was\n    taken. Readings allowed by the text are (a) age at the most recent visit, the visit whose\n    BCVA is reported for M83 and M75, and (b) age at data collection for the study (2024). Age\n    takes the default tolerance of 10%. Reproduced when diagnoses and sexes all match and ages\n    match under one reading; partially reproduced when diagnoses match but sex or age does not\n    for some patient.\n- id: inheritance-by-disease\n  statement: The RP mutations are all missense, dominant in IMPG1 and recessive (compound\n    heterozygous) in IMPG2; all VMD mutations are dominant (heterozygous), either missense or\n    nonsense.\n  source: Results, opening paragraph (before 3.1); Figure 1; Table 1\n  quote: Our findings show all missense mutations for the RP phenotype with dominant inheritance in\n    IMPG1 and recessive in IMPG2 ... all patients expressing VMD harvest dominant mutations,\n    which can be either mis- or non-sense\n  depends_on:\n  - table1-genotypes\n  - table1-diagnosis-sex-age\n  criterion: Read from the genotypes and diagnoses of the two claims it depends on. Dominant\n    and recessive are the paper's reading of zygosity (one heterozygous variant is dominant,\n    two variants on different alleles recessive); family segregation is not reported. Reproduced\n    when the dataset's genotypes and diagnoses give the pattern stated.\n- id: table1-bcva\n  statement: BCVA (OD and OS) is F32 20/25 and 20/25; M83 20/70 and 20/30; M75 20/40 and 20/40;\n    M82 20/30 and 20/25; M73 20/100 and 20/50; F57 20/20 and 20/20; M34 20/20 and 20/20.\n  source: Table 1; Results, 3.1 and 3.2, the paragraph on each patient\n  inferred: The values of all seven patients are in Table 1; the text of 3.1 and 3.2 repeats\n    each patient's values in separate paragraphs.\n  criterion: Snellen fractions must match exactly, eye by eye (no tolerance, as Snellen acuity\n    is read in discrete lines). The paper says for M83 and M75 that the value is from the most\n    recent visit and does not say so for the others. Readings are (a) the most recent visit\n    recorded and (b) any visit recorded. Reproduced when all 14 eyes match under one reading;\n    partially reproduced when at least 10 do; not reproduced otherwise.\n- id: f32-sector-rp-phenotype\n  statement: Patient F32 has sector RP of the inferior retina; FF shows inferior sectoral bone\n    spicule pigmentation, FAF reduced autofluorescence, SD-OCT a normal foveal architecture\n    without significant thinning, and GVF a superior depression in both eyes.\n  source: Results, 3.1 RP Patients, paragraph on Patient F32; Figure 2A,B\n  quote: Clinically, Patient F32 presented with sector RP primarily affecting the inferior retina (\n    Figure 2 A,B). ... The FF examination revealed dystrophy of the inferior retina,\n    characterized by sectorial bone spicule pigmentation (yellow arrows). The FAF imaging\n    showed reduced autofluorescence corresponding to a superior visual field defect in both\n    eyes\n  criterion: The paper grades its images by clinical inspection and gives no quantitative\n    measure; the arrows in Figure 2A,B mark the features. Each feature (inferior bone spicule\n    pigmentation on FF, reduced FAF, foveal architecture without significant thinning on\n    SD-OCT, superior depression on GVF) is judged by viewing the patient's image of that\n    modality and eye against the place the Figure 2 legend marks. Reproduced when the\n    dataset holds the four modalities for both eyes and each feature is visible; partially\n    reproduced when some are; blocked for a modality the dataset lacks. This visual reading is\n    the only method the paper allows and is recorded as a deviation.\n- id: m83-rp-phenotype\n  statement: Patient M83 has bilateral outer retinal atrophy sparing the central fovea with a\n    bull's eye pattern, 360 degree bone spicules, pale discs and attenuated vessels on FF;\n    reduced FAF; an inferior residual crescent and small central field on GVF; and diffuse\n    ellipsoid zone and outer nuclear layer loss on SD-OCT, sparing part of the central fovea in\n    the left eye.\n  source: Results, 3.1 RP Patients, paragraph on Patient M83; Figure 2C,D\n  quote: The FF revealed bilateral outer retinal atrophy sparing the central fovea, with a bull's\n    eye pattern surrounding the fovea ( Figure 2 C,D). ... The GVF demonstrated an inferior\n    residual crescent in both eyes and a small central visual field. The SD-OCT shows diffuse\n    loss of the ellipsoid zone and outer nuclear layer, sparing part of the central fovea in\n    the left eye.\n  criterion: As for f32-sector-rp-phenotype, by visual inspection of each modality and eye\n    against the features the text and the Figure 2C,D legend name (atrophy, bull's eye pattern,\n    bone spicules, reduced FAF, GVF crescent and central field, ellipsoid loss). Reproduced\n    when every named feature is visible; partially reproduced when some are; blocked for a\n    modality the dataset lacks.\n- id: m75-vmd-phenotype\n  statement: Patient M75 has bilateral subretinal vitelliform material in the macula on SD-OCT,\n    macular hypopigmentation on FF, FAF hypo-autofluorescence in the right macula and\n    hyper-autofluorescence in the left, early blockage and late window defects on FA, and a\n    superior macular nevus.\n  source: Results, 3.2 VMD Patients, paragraph on Patient M75; Figure 3A,B\n  quote: Subretinal vitelliform material was detected bilaterally in the macula by SD-OCT ( Figure 3\n    A,B). The FF shows hypopigmentation in the macula of both eyes. Hypo-autofluorescence,\n    suggesting retinal atrophy, was observed in the right macula, while hyper-autofluorescence,\n    indicative of vitelliform deposits, was noted in the left macula using FAF.\n  criterion: By visual inspection of each modality and eye, as for f32-sector-rp-phenotype. The\n    text and the legend disagree on the left eye's FAF; the legend says \"FAF shows\n    hypo-autofluorescence in the right and left macula\". Both readings are named; the FAF\n    feature holds when the left macula is hyper-autofluorescent (text) or hypo-autofluorescent\n    (legend), and the notebook says which. Reproduced when the SD-OCT, FF, FAF and FA features\n    are visible; partially reproduced when some are.\n- id: m82-vmd-phenotype\n  statement: Patient M82 has late-stage VMD with foveal atrophy; SD-OCT shows an attenuated\n    ellipsoid and retinal thinning in the right eye and a vitelliform lesion with small\n    ellipsoid disruption in the left; FF shows foveal hypopigmentation and FA window defects in\n    both eyes.\n  source: Results, 3.2 VMD Patients, paragraph on Patient M82; Figure 3C,D\n  quote: SD-OCT of the right eye showed attenuated ellipsoid and retinal thinning, while the left eye\n    displayed a vitelliform lesion with a small ellipsoid zone disruption. The FF shows\n    hypopigmentation of the fovea in both eyes. The FFA demonstrates a bilateral window defect.\n  criterion: By visual inspection of each modality and eye, as for f32-sector-rp-phenotype,\n    against the features of the text and the Figure 3C,D legend. Reproduced when every named\n    feature is visible; partially reproduced when some are.\n- id: m73-vmd-phenotype\n  statement: Patient M73 has bilateral macular subretinal hyporeflective spaces and ellipsoid\n    disruption on SD-OCT, foveal hypopigmentation, dot-blot hemorrhages and peripheral\n    cobblestone degeneration on FF, and bilateral hyper-autofluorescence on FAF.\n  source: Results, 3.2 VMD Patients, paragraph on Patient M73; Figure 3E,F\n  quote: Patient M73, a 73-year-old male, presented with bilaterally macular subretinal\n    hyporeflective spaces on SD-OCT, suggesting the reabsorption of vitelliform material (\n    Figure 3 E,F). Additional findings included ellipsoid disruption.\n  criterion: By visual inspection of each modality and eye, as for f32-sector-rp-phenotype.\n    The text does not say which eye has the ellipsoid disruption; the Figure 3E,F legend says\n    the right eye, and either eye satisfies the feature. Reproduced when every named feature is\n    visible; partially reproduced when some are.\n- id: f57-vmd-phenotype\n  statement: Patient F57 has subretinal vitelliform lesions in the macula of both eyes on\n    SD-OCT, foveal hypopigmentation on FF, and bilateral hypo-autofluorescence on FAF, more\n    pronounced in the left eye.\n  source: Results, 3.2 VMD Patients, paragraph on Patient F57; Figure 3G,H\n  quote: exhibiting subretinal vitelliform lesions in the macula of both eyes on SD-OCT ( Figure 3\n    G,H). ... FAF showed hypo-autofluorescence bilaterally, which was more pronounced in the left\n    eye.\n  criterion: By visual inspection of each modality and eye, as for f32-sector-rp-phenotype.\n    \"More pronounced\" is judged by comparing the extent of the hypo-autofluorescent area in the\n    two eyes' FAF images; the paper gives no measure. Reproduced when every named feature is\n    visible; partially reproduced when some are.\n- id: m34-vmd-phenotype\n  statement: Patient M34 has bilateral subretinal vitelliform lesions on SD-OCT, glaucomatous\n    optic nerves and mild macular hypopigmentation on FF, and faint hyper-autofluorescence on\n    FAF.\n  source: Results, 3.2 VMD Patients, paragraph on Patient M34; Figure 3I,J\n  quote: The SD-OCT shows subretinal vitelliform lesions on both eyes. The FF is primarily indicative\n    of glaucomatous optic nerves and mild macular hypopigmentation. FAF showed faint\n    hyper-autofluorescence.\n  criterion: By visual inspection of each modality and eye, as for f32-sector-rp-phenotype.\n    The text and the legend disagree on FAF; the Figure 3I,J legend says \"The FF and FAF reveal\n    bilateral hypopigmentation and hypo-autofluorescence\". Both readings are named; the FAF\n    feature holds under either, and the notebook says which. Reproduced when every named\n    feature is visible; partially reproduced when some are.\n- id: rp-superior-field-no-cme\n  statement: Both RP patients have superior visual field limitation (inferior retina affected\n    first), and neither has cystoid maculopathy.\n  source: Discussion, paragraph 3 (on Patient M83 and the RP patients)\n  quote: Both RP patients experienced visual field limitations in the superior visual field. ...\n    Cystoid maculopathy did not occur in either young or old patients.\n  depends_on:\n  - f32-sector-rp-phenotype\n  - m83-rp-phenotype\n  criterion: The superior limitation is read from the GVF of F32 and M83 by visual inspection;\n    the absence of cystoid maculopathy from their SD-OCT, where cystoid spaces are looked for in\n    the macula of each eye (Methods 2.1 names cystoid macular edema as an OCT indicator for RP).\n    The paper gives no test. Reproduced when both GVFs show the superior limitation and no\n    macular SD-OCT shows cystoid spaces; not reproduced when either fails.\n- id: vmd-acuity-preserved\n  statement: In most VMD patients visual acuity was not significantly reduced; the only\n    exception is M73 (20/100 OD, 20/50 OS).\n  source: Discussion, paragraph 5\n  quote: Interestingly, in most VMD patients, visual acuity was not significantly reduced. The only\n    exception is patient M73, who has a BCVA of 20/100 OD and 20/50 OS.\n  depends_on:\n  - table1-bcva\n  criterion: The paper gives no threshold for a significant reduction. Its own text counts M75\n    (20/40 in both eyes) as not reduced and M73 (20/50 in the better eye) as reduced, so the\n    threshold lies between 20/40 and 20/50 and every threshold in that range sorts the Table 1\n    values the same way. Reproduced when, among the five VMD patients, M73 is the only one with\n    BCVA worse than 20/40 in either eye.\n- id: m73-f57-similar-lesions\n  statement: The two unrelated carriers of IMPG2 p.Arg964* (M73 and F57) have similar\n    vitelliform macular lesions, but the older (M73) has peripheral cobblestone lesions and\n    macular lesions with increased autofluorescence.\n  source: Discussion, paragraph 6\n  quote: Both patients have similar vitelliform macular lesions. However, the oldest patient (M73)\n    presents with peripheral cobblestone lesions, and the macular lesions have increased\n    autofluorescence.\n  depends_on:\n  - m73-vmd-phenotype\n  - f57-vmd-phenotype\n  criterion: The paper gives no measure of similarity. Judged by visual inspection of the two\n    patients' SD-OCT and FAF images; reproduced when both show macular vitelliform lesions on\n    SD-OCT, M73's FAF is hyper-autofluorescent where F57's is hypo-autofluorescent, and M73's FF\n    shows peripheral cobblestone degeneration that F57's does not.\n- id: m73-eog-normal\n  statement: Patient M73, who also carries a BEST1 variant, had a normal EOG, which the authors\n    read as against Best disease.\n  source: Discussion, paragraph 5 (on Patient M73)\n  quote: However, the patient's EOG results were normal, a finding inconsistent with Best disease\n    but more indicative of IMPG2-associated retinal dystrophy.\n  criterion: The paper reports no EOG values, no Arden ratio and no normal range, and its Methods\n    do not describe the EOG. Reproduced when the dataset holds M73's EOG and it is reported as\n    normal there, or when its light-peak to dark-trough (Arden) ratio is in the normal range the\n    recording gives; blocked when the dataset holds no EOG. The normal range is not fixed by\n    the paper and is recorded as open.\n- id: other-gene-variants\n  statement: Besides their IMPG variants, F32 carries a JAG1 variant, M73 a BEST1 variant, and\n    M83 heterozygous variants of uncertain significance in ALMS1, CEP164, COL11A1, CPLANE1,\n    EYS, KIF7, NPHP4 and PHYH.\n  source: Discussion, paragraphs 2, 3 and 5\n  quote: It is also important to note that this patient had two diseased gene variants: IMPG1 and\n    JAG1 .\n  criterion: Reproduced when the dataset's genetic reports list each of the named genes for\n    the named patient; partially reproduced when some are listed; blocked when the dataset\n    holds no genetic report beyond the IMPG variants. The quote states the JAG1 variant of F32;\n    the BEST1 variant of M73 and the M83 gene list are stated in Discussion paragraphs 5 and 3.\n- id: table2-pathogenicity\n  statement: In silico tools predict all IMPG2 variants and the novel IMPG1 p.Asp423Glu to be\n    pathogenic, and IMPG1 p.Leu740Phe to be likely benign, with the scores of Table 2.\n  source: Results, 3.3 Pathogenicity Prediction; Table 2\n  quote: In IMPG1, the novel variant p.Asp423Glu is predicted to be pathogenic, while the known\n    variant p.Leu740Phe is considered likely benign.\n  data: with_inputs\n  expected:\n  - quantity: SIFT score, IMPG1 p.Leu740Phe\n    value: 0.09\n    tolerance: 0.009\n  - quantity: PolyPhen score, IMPG1 p.Leu740Phe\n    value: 0.575\n    tolerance: 0.0575\n  - quantity: CADD score, IMPG1 p.Leu740Phe\n    value: 3.6\n    tolerance: 0.36\n  - quantity: SIFT score, IMPG1 p.Asp423Glu\n    value: 0.02\n    tolerance: 0.002\n  - quantity: PolyPhen score, IMPG1 p.Asp423Glu\n    value: 0.98\n    tolerance: 0.098\n  - quantity: CADD score, IMPG1 p.Asp423Glu\n    value: 2.5\n    tolerance: 0.25\n  - quantity: PolyPhen score, IMPG2 p.Cys1019Tyr\n    value: 0.996\n    tolerance: 0.0996\n  - quantity: CADD score, IMPG2 p.Cys1019Tyr\n    value: 25.8\n    tolerance: 2.58\n  - quantity: PolyPhen score, IMPG2 p.Arg131Cys\n    value: 0.645\n    tolerance: 0.0645\n  - quantity: CADD score, IMPG2 p.Arg131Cys\n    value: 21.7\n    tolerance: 2.17\n  - quantity: PolyPhen score, IMPG2 p.Leu249Phe\n    value: 0.998\n    tolerance: 0.0998\n  - quantity: CADD score, IMPG2 p.Leu249Phe\n    value: 22.6\n    tolerance: 2.26\n  - quantity: CADD score, IMPG2 p.Arg964*\n    value: 11.2\n    tolerance: 1.12\n  - quantity: CADD score, IMPG2 p.Arg1088*\n    value: 13.4\n    tolerance: 1.34\n  criterion: Uses outside tools, not the dataset. Scores are recomputed with the tools of\n    Methods 2.2 (SIFT, PolyPhen-2, MutationTaster, CADD, FATHMM) for the variants of Table 1.\n    The paper names no tool version, genome build or reference transcript; PolyPhen-2, CADD,\n    MutationTaster and FATHMM were accessed on 10 November 2024, SIFT with no date. Readings for\n    the build are GRCh37 and GRCh38, and for the transcript the canonical (MANE Select) one of\n    each gene; CADD version is the one current in November 2024 (v1.7) or the one before\n    (v1.6). Scores take the default 10%; SIFT scores of 0 must be 0 (below 0.05, the damaging\n    range). The FATHMM and MutationTaster columns of Table 2 are reported, not tested, as the\n    flattened table cannot show which numbers belong to which tool beyond the column order\n    (FATHMM 0.0376, 0.0577, 0.0076, 0.011, 0.0513 for the IMPG2 variants; MutationTaster 22,\n    45, 46, 91, 78, 58, 29 in table order). Reproduced when, under one reading, the scores are\n    within tolerance and the Prediction column (pathogenic for all but p.Leu740Phe) is\n    matched; partially reproduced when the predictions match but some scores do not.\n- id: asp423glu-novel\n  statement: IMPG1 p.Asp423Glu, found in M75, is a novel variant with no ClinVar entry, and its\n    association with VMD is reported here for the first time.\n  source: Table 2 (Existing Variant ID column); Discussion, paragraph 4\n  quote: Notably, patient M75 harbored a novel missense mutation, p.Asp423Glu, in IMPG1, marking its\n    first reported association with VMD.\n  data: with_inputs\n  criterion: Uses outside data (ClinVar, dbSNP), not the dataset. The paper does not say which\n    release it searched; readings are the releases current at submission (November 2024) and\n    the release current when the attempt is run. Reproduced when no entry for IMPG1 c.1269C>A\n    (p.Asp423Glu) existed in the November 2024 release; a later entry is reported but does not\n    change the outcome.\n- id: table3-destabilizing\n  statement: All five missense variants are predicted to destabilize the protein by every tool\n    (all ΔΔG negative), and p.Leu249Phe shows the largest destabilizing effect.\n  source: Results, 3.4 Prediction of Protein Stability for Point Mutations; Table 3\n  quote: Our analysis revealed that all the variants, including p.Leu740Phe, p.Asp423Glu,\n    p.Cys1019Tyr, p.Leu249Phe, and p.Arg131Cys, lead to destabilizing effects on the proteins\n    ... Specifically, the p.Leu249Phe variant exhibited the largest destabilizing effect\n  data: with_inputs\n  expected:\n  - quantity: mCSM ΔΔG, IMPG2 p.Leu249Phe\n    value: -1.743\n    tolerance: 0.1743\n    unit: kcal/mol\n  - quantity: DUET ΔΔG, IMPG2 p.Leu249Phe\n    value: -1.77\n    tolerance: 0.177\n    unit: kcal/mol\n  - quantity: MuPRO ΔΔG, IMPG2 p.Leu249Phe\n    value: -1.525\n    tolerance: 0.1525\n    unit: kcal/mol\n  criterion: Uses outside tools, not the dataset. ΔΔG is recomputed with mCSM, SDM, DUET,\n    iMutant and MuPRO (Methods 2.4) for the five missense variants; the 25 values of Table 3\n    take the default 10% each, and the three listed under expected are those the ranking rests\n    on. mCSM, SDM and DUET need a structure; Methods 2.3 says it is the I-TASSER model with the\n    highest confidence score and over 80% of residues in favored Ramachandran regions, and the\n    model is not deposited, so a rerun of I-TASSER is the only reading and its stochastic\n    output is a source of difference (recorded as a deviation). iMutant and MuPRO run from\n    sequence; the paper names no UniProt entry, and the canonical isoforms (IMPG1 Q17R60,\n    IMPG2 Q9BZV3) are the reading used. The paper names no unit; the tools report kcal/mol. All\n    negative is tested on every value. \"Largest\" is not defined; readings are (a) the mean\n    ΔΔG over the five tools, (b) the largest magnitude in a majority of tools, (c) the largest\n    in every tool. Table 3 itself satisfies (a) and (b) but not (c) (SDM gives p.Cys1019Tyr and\n    iMutant p.Arg131Cys a larger magnitude). Reproduced when all signs are negative and\n    p.Leu249Phe is largest under (a) or (b).\n- id: impg1-interactions-unchanged\n  statement: In IMPG1, neither p.Asp423Glu nor p.Leu740Phe changes hydrogen bonds, van der Waals\n    interactions or polar contacts significantly.\n  source: Results, 3.5, paragraph 1; Figure 4A,B\n  quote: In IMPG1, no significant differences were observed in hydrogen bonds, van der Waals\n    interactions or polar contacts between the reference and mutant proteins.\n  data: with_inputs\n  criterion: A claim of absence; the paper names no test or threshold. Uses outside tools\n    (DynaMut, Methods 2.5, on the I-TASSER models of Methods 2.3, not deposited). Reproduced\n    when DynaMut lists the same hydrogen bonds, van der Waals and polar contacts of residue 423\n    and residue 740 in the reference and mutant models, as Figure 4A,B shows; the contacts\n    gained or lost are reported either way. The model is re-predicted, which is recorded as a\n    deviation.\n- id: impg2-interactions-changed\n  statement: In IMPG2, p.Cys1019Tyr replaces the polar bond of Cys1019 with Ser1023 and its\n    hydrogen bond with Cys1036 by new bonds with Ser1023, Gln1017 and Cys1025; p.Leu249Phe loses\n    the hydrogen bonds of Leu249 with Val305, Lys252, Leu373 and Val307; p.Arg131Cys loses the\n    hydrogen bond with Tyr134 and a van der Waals interaction.\n  source: Results, 3.5, paragraphs 3 to 5; Figure 4C to 4E\n  quote: In the reference protein, Cysteine 1019 interacts with Serine 1023 through polar bonds and\n    with Cysteine 1036 via hydrogen bonds ( Figure 4 C). In the mutant protein, Tyrosine 1019\n    replaces Cysteine 1019, disrupting these original interactions. Instead, Tyrosine 1019\n    forms new bonds with Serine 1023, Glutamine 1017, and Cysteine 1025.\n  data: with_inputs\n  criterion: Uses outside tools (DynaMut on re-predicted I-TASSER models, as for\n    impg1-interactions-unchanged). The contacts of residues 1019, 249 and 131 in reference and\n    mutant are compared with the residues the text names. The text names the van der Waals\n    partner of Arg131 as Gln1236 and then as His135; both readings are named and either\n    matches. Reproduced when the named contacts are lost and, for p.Cys1019Tyr, the named new\n    contacts appear, for all three variants; partially reproduced for one or two.\n- id: table4-impg1-physicochemical\n  statement: ProtParam gives reference IMPG1 a molecular weight of 89,387 Da, pI 4.79,\n    instability index 53.57 and aliphatic index 75.63; p.Asp423Glu raises the weight (89,419),\n    pI (4.81) and instability index (53.76), and p.Leu740Phe raises the weight (89,421) and\n    lowers the aliphatic index (75.14).\n  source: Results, 3.5, paragraph 2; Table 4\n  quote: The molecular weight increased from 89.387 KDa in the reference protein to 89.419 KDa in\n    the p.Asp423Glu mutant and 89.421 KDa in the p.Leu740Phe mutant\n  data: with_inputs\n  expected:\n  - quantity: molecular weight, reference IMPG1\n    value: 89387\n    tolerance: 0.5\n    unit: Da\n  - quantity: molecular weight, p.Asp423Glu\n    value: 89419\n    tolerance: 0.5\n    unit: Da\n  - quantity: molecular weight, p.Leu740Phe\n    value: 89421\n    tolerance: 0.5\n    unit: Da\n  - quantity: theoretical pI, reference\n    value: 4.79\n    tolerance: 0.005\n  - quantity: theoretical pI, p.Asp423Glu\n    value: 4.81\n    tolerance: 0.005\n  - quantity: theoretical pI, p.Leu740Phe\n    value: 4.79\n    tolerance: 0.005\n  - quantity: total number of atoms, reference\n    value: 12450\n    tolerance: 0\n  - quantity: total number of atoms, p.Asp423Glu\n    value: 12457\n    tolerance: 0\n  - quantity: total number of atoms, p.Leu740Phe\n    value: 12451\n    tolerance: 0\n  - quantity: instability index, reference\n    value: 53.57\n    tolerance: 0.005\n  - quantity: instability index, p.Asp423Glu\n    value: 53.76\n    tolerance: 0.005\n  - quantity: instability index, p.Leu740Phe\n    value: 53.16\n    tolerance: 0.005\n  - quantity: aliphatic index, reference\n    value: 75.63\n    tolerance: 0.005\n  - quantity: aliphatic index, p.Asp423Glu\n    value: 75.63\n    tolerance: 0.005\n  - quantity: aliphatic index, p.Leu740Phe\n    value: 75.14\n    tolerance: 0.005\n  - quantity: GRAVY, reference\n    value: -0.482\n    tolerance: 0.0005\n  - quantity: GRAVY, p.Asp423Glu\n    value: -0.474\n    tolerance: 0.0005\n  - quantity: GRAVY, p.Leu740Phe\n    value: -0.483\n    tolerance: 0.0005\n  criterion: Uses an outside tool (ExPASy ProtParam, Methods 2.6), not the dataset. Tolerances\n    are half the last printed digit, not 10%, because ProtParam is deterministic for a given\n    sequence and the finding is a difference between forms far smaller than 10% of any value.\n    The paper names no sequence; readings are (a) the canonical UniProt IMPG1 sequence\n    (Q17R60, 797 residues) and (b) the same without its signal peptide. Reproduced when every\n    value matches under one reading; partially reproduced when the directions of change stated\n    in the text (weight up for both, pI and instability index up for p.Asp423Glu, aliphatic\n    index down for p.Leu740Phe) hold but some values do not. A single Asp to Glu change adds\n    one CH2 (14 Da, 3 atoms), not the 32 Da and 7 atoms of Table 4, so the p.Asp423Glu weight\n    and atom count may not reproduce under either reading; this is reported. The Discussion\n    (paragraph 2) attributes the higher pI and instability index to p.Leu740Phe, which Table 4\n    does not show; the claim follows Results 3.5 and Table 4.\n- id: gnomad-frequencies\n  statement: In gnomAD, IMPG2 p.Cys1019Tyr occurs in about 1 in 93,300 European (non-Finnish)\n    individuals; p.Arg131Cys in about 1 in 4100 European (non-Finnish) and 1 in 3000 Middle\n    Eastern; p.Arg964* in about 1 in 18,700 African/African American and 1 in 59,000 European\n    (non-Finnish); and IMPG1 p.Leu740Phe in about 1 in 332 European (non-Finnish).\n  source: Results, 3.1 RP Patients, paragraph on Patient M83; Results, 3.2 VMD Patients,\n    paragraph on M73 and F57; Discussion, paragraph 2\n  quote: The Cys1019Tyr variant is a rare mutation found exclusively in the European (non-Finnish)\n    population, with an estimated frequency of approximately 1 in 93,300 individuals.\n  data: with_inputs\n  expected:\n  - quantity: p.Cys1019Tyr, European (non-Finnish), individuals per carrier\n    value: 93300\n    tolerance: 9330\n  - quantity: p.Arg131Cys, European (non-Finnish), individuals per carrier\n    value: 4100\n    tolerance: 410\n  - quantity: p.Arg131Cys, Middle Eastern, individuals per carrier\n    value: 3000\n    tolerance: 300\n  - quantity: p.Arg964*, African/African American, individuals per carrier\n    value: 18700\n    tolerance: 1870\n  - quantity: p.Arg964*, European (non-Finnish), individuals per carrier\n    value: 59000\n    tolerance: 5900\n  - quantity: p.Leu740Phe, European (non-Finnish), individuals per carrier\n    value: 332\n    tolerance: 33.2\n  criterion: Uses outside data (gnomAD), not the dataset. The paper names no gnomAD version and\n    does not say whether \"1 in N\" is the inverse of allele frequency or of carrier frequency.\n    A Middle Eastern population is in gnomAD v3.1 and later, so the version readings are v3.1.2\n    genomes and v4.1 (exomes and genomes joint, and each alone); the frequency readings are\n    1/allele frequency and 1/(2 x allele frequency). Default 10% tolerance. Reproduced when\n    every value matches under one combination of readings; partially reproduced when at least\n    four of the six do.\n"
}
```

```
File created successfully at: claims/001882/10.3390-genes16010043.yaml (file state is current in your context — no need to Read it back)
```

**Agent calls Bash**

```bash
sed -i 's/ (Q17R60, 797 residues)/ (Q17R60)/' claims/001882/10.3390-genes16010043.yaml && python tools/claims_check.py claims/001882/10.3390-genes16010043.yaml paper/10.3390-genes16010043.txt
```

Result: not kept, because it reads the paper's text.

**Agent**

Expected: a quote with a colon. I'll cut the quote at the colon with "...".

**Agent calls Edit**

```json
{
 "replace_all": false,
 "file_path": "claims/001882/10.3390-genes16010043.yaml",
 "old_string": "  quote: It is also important to note that this patient had two diseased gene variants: IMPG1 and\n    JAG1 .",
 "new_string": "  quote: It is also important to note that this patient had two diseased gene variants ... IMPG1\n    and JAG1 ."
}
```

```
The file claims/001882/10.3390-genes16010043.yaml has been updated successfully.
```

**Agent calls Bash**

```bash
python tools/claims_check.py claims/001882/10.3390-genes16010043.yaml paper/10.3390-genes16010043.txt
```

Result: not kept, because it reads the paper's text.

**Agent calls Bash**

```bash
grep -nE "—|rather" claims/001882/*.yaml; git status --short
```

```
?? .bash_profile
?? .bashrc
?? .gitconfig
?? .idea
?? .mcp.json
?? .profile
?? .ripgreprc
?? .vscode
?? .zprofile
?? .zshrc
?? claims/001882/
?? scripts
```

**Agent**

I wrote `claims/001882/10.3390-genes16010043.yaml`. The quote checker reports 25 claims, 23 quotes, 0 statistical values and 0 problems.

**Text read:** the version of record (open access, Europe PMC PMC11764596), including the Introduction, Methods, Results, Discussion, the legends of Figures 1 to 4, and Tables 1 to 4 inline. There was no PDF, but the tables were legible in the text. The paper names no supplement and links no code, so no code was read. Its Data Availability Statement says "No new data were created or analyzed", even though the dandiset is described by this paper.

**Claims:** 25 in total.
- **Quotes:** 23 have a quote. The other 2 have an `inferred` note: Table 1 sex, age and diagnosis, and Table 1 visual acuity (BCVA).
- **Statistics:** none. The paper reports no tests or intervals.
- **Expected values:** 5 claims have them: prevalence counts and percentages, Table 2 scores, Table 3 ΔΔG values, Table 4 ProtParam values, and gnomAD frequencies.
- **Criteria:** every claim has one.
- **Data:** 6 claims use outside tools or databases (`with_inputs`): pathogenicity scores, the novelty of p.Asp423Glu, stability, the two interatomic-interaction claims, and physicochemical properties. Two more (gnomAD frequencies and the novelty check against ClinVar) need public databases. The rest are clinical claims on the dataset: prevalence, ancestry, genotypes, inheritance, BCVA, the seven per-patient imaging phenotypes, the Discussion's findings, M73's EOG, and other gene variants.

**Details the paper leaves open, with the readings named:**
- **Imaging features:** the paper grades them by eye only, with no measure. The criterion is to inspect each modality and eye against the places the figure arrows mark. This is the only method the paper allows, and it is recorded as a deviation.
- **Text and legend disagree on autofluorescence:**
  - M75's left eye: hyper-autofluorescent in the text, hypo in the legend.
  - M34: faint hyper in the text, hypo in the legend.
  - Either reading counts.
- **Arg131's lost van der Waals partner:** the text names Gln1236 in one place and His135 in another. Either counts.
- **When ages were taken:** at the most recent visit, or at data collection in 2024.
- **Which BCVA visit:** the most recent, or any recorded visit.
- **"Not significantly reduced" acuity:** the text places the threshold between 20/40 and 20/50, and any value there sorts the patients the same way.
- **Table 2 scores:** the genome build (GRCh37 or GRCh38), the transcript (MANE Select), and the CADD version (v1.6 or v1.7) are not given.
- **Table 3, "largest destabilizing" for p.Leu249Phe:**
  - Readings: the mean over the five tools, a majority of tools, or every tool.
  - The table itself fails the "every tool" reading: SDM and iMutant each rank another variant larger.
- **Structural models:** I-TASSER models underlie the structure-based stability tools and DynaMut. They were not deposited, so they must be re-predicted.
- **Protein sequence:** the paper names none. The readings are the canonical UniProt entry (IMPG1 Q17R60, IMPG2 Q9BZV3), with or without the signal peptide for ProtParam.
- **gnomAD:** the version is not given; the readings are v3.1.2, or v4.1 joint, exomes or genomes. "1 in N" is not defined; the readings are 1/allele frequency or 1/(2 × allele frequency).
- **Database releases:** the ClinVar release is not given; the reading is the one current in November 2024.
- **EOG:** the paper gives no normal range and no method.

**Inconsistencies in the paper, noted in the criteria:**
- The prevalence percentages are truncated (7/480 is 1.458%, printed as 1.45%). Both readings fall within tolerance.
- In Table 4, the p.Asp423Glu row (+32 Da, +7 atoms) does not match a single Asp to Glu change (+14 Da, +3 atoms).
- The Discussion credits the higher pI and instability index to p.Leu740Phe, which Table 4 contradicts.
- Table 1 misspells IMPG1 as "IMGP1".

**Missing from the paper:** nothing a claim needed to be written. The EOG values, the tool versions and the structural models are absent, and the claims that use them name this as open.

## End of run

15 turns, 4 minutes, result: success.
